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Abstract
C-reactive protein (CRP) is a positive, acute-phase protein. Plasma levels rise dramatically in response to tissue injury or in-
flammation and fall rapidly after recovery or treatment. Antibody-based human CRP test systems do not readily detect CRP from
other animals due to the species specificity of antibodies directed against human CRP. Thus, generic systems for CRP detection,
based solely on the interaction between CRP and phosphocholine (PC), have been developed. PC–bovine serum albumin (PC–BSA)
conjugates were produced and either labeled with horseradish peroxidase to facilitate CRP detection in a CRP enzyme-linked
sorbent assay (ELSA) or coupled to carboxy-modified microspheres to facilitate the nonenzymatic, turbidimetric detection of CRP.
The CRP-ELSA is a competitive assay, where the total assay time is 45min, the assay sensitivity is 1.06mg/L CRP, and the dynamic
range of the assay is 0–500mg/L. When PC–BSA conjugate is covalently coupled to carboxylated microspheres, agglutination
occurs in the presence of CRP, the extent of which depends on the quantity of CRP present in the sample. Total assay time is 5min
with a dynamic range of 25–500mg/L. Both assay formats are capable of accurately detecting human CRP and the CRP-ELSA can
detect canine CRP as a disease state indicator.
 2003 Elsevier Science (USA). All rights reserved.
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C-reactive protein (CRP)1 is a member of a highly
conserved family of proteins, the pentraxins. It is com-
posed of five identical subunits bound noncovalently to
each other in a cyclic pentameric structure [1]. In hu-
mans, CRP is a positive acute-phase protein and plasma
levels of CRP elevate dramatically in response to tissue
injury, infection, or inflammation from less than one to
several hundred milligrams per liter [2]. Plasma CRP
levels fall just as rapidly after recovery or treatment and
it is now known that the half-life of plasma CRP is
approximately 19 h [3]. Recent studies have shown that
measurement of CRP levels within the normal range has
significance in the risk assessment of cardiovascular
disease and circulatory disorders such as peripheral
vascular disease [4].
Conventional assay systems for the detection of CRP,
such as immunonephelometry, immunoturbidimetry,
immunoluminometry, and enzyme-linked immunosor-
bent assay (ELISA), all depend upon the availability of
either polyclonal or monoclonal antibodies [5]. In
practice, the reproducibility and cost of antibody supply
are significant rate-limiting factors with respect to the
reproducible and reliable manufacture of these CRP
detection systems. Polyclonal antibody production is
unsatisfactory for the large-scale production of antibody
reagent due to the variability in immune response in
different animals which can result in the production of
antibody preparations of variable specificity and sensi-
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tivity of detection [6,7]. Furthermore, species-specific
CRP test systems do not readily detect CRP from un-
related species due to the absence of common antigenic
sites [8]. This factor is of significant concern from the
viewpoint of animal welfare, whereby a generic CRP
detection system for veterinary specimens would greatly
facilitate improvement both in the diagnosis of animal
disease and in animal husbandry methods. The re-
quirement therefore exists for a nonimmunological test
system for the multispecies detection of CRP to over-
come the aforementioned limitations.
Calcium-mediated CRP binding to immobilized
phosphocholine (PC) in association with enzyme-labeled
antibody detection of captured CRP, has been proposed
as an alternative CRP detection methodology [9,10].
Both of these assays involve coating microwells with
PC-conjugated bovine serum albumin (PC–BSA) fol-
lowed by the addition of CRP. The quantity of CRP is
then immunometrically determined by indirect ELISA
using goat IgG [anti-CRP] followed by a commercial
rabbit anti-species IgG–alkaline phosphate conjugate [9]
or rabbit IgG [anti-CRP] followed by the addition of
enzyme-labeled donkey anti-rabbit IgG [11]. The preci-
sion of the latter assay was found to be 12:3 5:3% CV
(percentage coefficient of variation) over a range of CRP
concentrations, while the sensitivity of detection was
observed to be 2.5mg/L CRP. More recently, another
test system exploiting CRP/PC interaction has been
described [12]: however, this test requires extensive sig-
nal amplification techniques such as fluorometric or
radioactive detection of CRP/PC complex and antibody-
mediated immobilization of the target CRP analyte as in
the aforementioned methods.
In the present study we undertook the development
of (i) an entirely nonimmunological assay (enzyme-
linked sorbent assay (ELSA)) for CRP detection based
solely on the calcium-dependent binding affinity of CRP
for phosphocholine and (ii) a turbidimetric assay for the
detection of CRP based on latex microsphere-labeled
PC–BSA, thereby eliminating the requirement for en-
zymatic detection and multiple wash steps.
Materials and methods
Materials
All materials were obtained from Sigma–Aldrich
Chemical Company (Dorset, UK) unless otherwise
indicated.
Conjugation of phosphocholine to bovine serum albumin
All manipulations were carried out at room tempera-
ture and were performed essentially as previously
described [10]. Briefly, cytidine 50-diphosphocholine
(CDPC) was subjected to periodate oxidation and added
to 5ml BSA (28mg/ml in 100mM sodium bicarbonate)
ðn ¼ 3Þ at (A) 70-, (B) 7-, and (C) 0.7-fold molar excess.
Stable Schiff bond formation occurred by subsequent
addition of 5ml 500mM sodium borohydride to each of
preparations A–C. Following PC–BSA conjugation, the
reaction mixture was dialyzed exhaustively at 4 C in ei-
ther 50mMpotassium phosphate, 1mMEDTA, 150mM
NaCl, pH 7.8, or 100mM sodium borate, pH 8.5, and
then stored at )20 C until used for conjugation to
horseradish peroxidase (HRP) or coupling to micro-
spheres.
Conjugation of HRP and PC–BSA
PC–BSA preparations (A–C) were each modified at
1mg/ml with 4-(maleimidomethyl)cyclohexanecarboxy-
lic acid N-hydroxysuccinimide ester (SMCC) by adding
7.5 ll 25mM SMCC in dimethylformamide per 1ml
PC–BSA solution and incubating at room temperature
for 30min. SMCC-activated PC–BSA (PC–BSA–SM
CC) preparations were dialyzed against 50mM potas-
sium phosphate, 1mMEDTA, 150mM sodium chloride,
pH 6.8. S-acetyl thioglycolic acid N-hydroxy- succini-
mide (SATA) was used to activate HRP as previously
described [13] and deblocked by the addition of 500mM
hydroxylamine (1/10 volume of SATA–HRP solution).
PC–BSA–SMCC preparations were added to three sep-
arate tubes containing deblocked HRP in the ratio of
1mg PC–BSA–SMCC per 4.6mg SATA–HRP, further
incubated for 5 h at room temperature, and dialyzed
against phosphate-buffered saline. PC–BSA–HRP con-
jugate formation was confirmed by functionality testing.
CRP-ELSA assay format
Human CRP standards (range 0–10mg/L) were pre-
pared by diluting a stock solution of CRP (24mg/ml) in
50mM 2-(N-morpholino)ethanesulfonic acid (MES),
25mM sodium chloride, 10mM calcium chloride, and
0.1% (v/v) Tween 20, pH 6.0. PC–BSA–HRP conjugate
(1/8000 dilution) and specimens for analysis were also
diluted in this buffer. Next, 50 ll of standards or speci-
mens and 50 ll of the conjugate were added into mi-
crowells previously coated with human CRP (100 ng/
well human CRP) (Fig. 1A). After incubation at room
temperature for 30min, the microwells are washed four
times with 50mM Tris–HCl, 25mM sodium chloride,
10mM calcium chloride, 0.1% (v/v) Tween 20, pH 7.4.
Tetramethylbenzidine (2.08mM; 100 ll) was added per
well followed by a 15-min incubation (Fig. 1A). The
reaction was stopped by adding 100 ll 1N H2SO4 and
the absorbance was read at 450/630 nm followed by
calculation of specimen [CRP] from the standard curve.
This CRP-ELSA was validated with regard to assay
parameters (time, temperature, buffer conditions), assay
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sensitivity and reproducibility, linearity of dilution, and
multispecies CRP detection.
Covalent coupling of PC–BSA to carboxy-modified
microparticles
Carboxy-modified microspheres (0.21 lM diameter;
10% (w/v); 100 ll), obtained from Bangs Laboratories
(Fishers, IN), were activated following addition of
100 ll 500mM MES, pH 6.1, 500 ll, deionized water,
230 ll sulfo N-hydroxysulfosuccinamide (50mg/ml),
and 24 ll 1-ethyl-3-(3-dimethylaminopropyl)carbodii-
mide (10mg/ml) for 30min. Following centrifugation
(10,000g for 20min), microspheres were twice resus-
pended by sonication in 1ml 50mM MES, pH 6.1. Fi-
nally, the microspheres were resuspended by sonication
in 1ml of PC–BSA protein stock (1mg/ml) in 100mM
sodium borate, pH 8.5, and mixed at room temperature
for 1 h. Then, 250mM ethanolamine hydrochloride in
100mM sodium borate, pH 8.5 (50 ll), was added fol-
lowed by centrifugation as above and microspheres re-
suspension in 1ml of 10mg/ml BSA in 100mM sodium
borate, pH 8.5. Finally, the microspheres (1% (w/v)
suspension) were washed twice, resuspended in 1ml of
50mM Tris–HCl, 25mM sodium chloride, 10mM cal-
cium chloride, pH 7.4, with sonication, and stored at
4 C until required for use.
Turbidimetric assay format
Prior to specimen addition, PC–BSA-coated micro-
spheres were diluted to 0.03% (w/v) in microsphere dil-
uent comprising 0.4% (w/v) PEG 6000 in 100mM
glycine, 90mM sodium chloride, 10mM calcium chlo-
ride, 0.04% (w/v) sodium azide, pH 7.6, to give ‘‘work-
ing reagent.’’ Working reagent, standards, and
specimens were loaded onto a Cobos Mira autoanalyzer
(Roche Diagnostics, Rotkreuz, Switzerland) programed
to dispense either standards or specimens (10 ll each)
along with working reagent (490 ll) into reaction cu-
vettes and brought to 37 C (Fig. 1B). The reaction was
initiated by addition of the working reagent and allowed
to proceed at 37 C for 5min. The absorbance (550 nm)
of all standards and specimens was determined at T ¼ 0
and at T ¼ 5min after which time it was observed that
PC–CRP binding was complete (data not shown). Upon
completion of the analysis, the change in absorbance
(DA) value for each standard and specimen was com-
puted and specimen CRP concentrations were calcu-
lated from a plot of DA550 nm (standards) versus [CRP]
(mg/L). The turbidimetric-CRP (t-CRP) assay was val-
idated with regard to assay parameters (time, tempera-
ture, buffer conditions), National Institute for Biological
Standards and Control (Hertfordshire, UK) human
C-reactive protein (1st International Standard; Code
85/506) detection, assay sensitivity, and linearity of
dilution.
Results
Preparation of PC–BSA–HRP conjugates
Following modification of BSA at (A) 70-, (B) 7-, and
(C) 0.7-fold molar excess of CDPC, preparations were
further activated by SMCC prior to HRP conjugation.
Analysis of PC–BSA confirmed the presence of 0.7, 3.7,
and 3.2 maleimide groups for preparations A, B, and C,
respectively. Subsequent to HRP conjugation, no evi-
dence of high-molecular-weight PC–BSA–HRP conju-
gate formation was observed by either SDS–PAGE or
Western blot analysis using IgG (anti-bovine serum al-
bumin) (data not shown). Therefore, in the absence of
conjugate visualization, extensive functional testing was
undertaken to confirm conjugate formation.
The successful formation of functional PC–BSA–
HRP conjugates was confirmed using the ELSA assay
format except that microwells were precoated with ei-
ther CRP (1 or 10 lg/ml) or BSA (1 lg/ml). In the ab-
sence of purified CRP, the PC–BSA–HRP conjugate
bound to the CRP-coated microwells, however, when
CRP was present in the specimen, even at concentra-
tions as low as 0.1mg/L, the absorbance decreased with
increasing concentrations of CRP (Fig. 2A). The opti-
mal PC–BSA–HRP conjugate (CM-3A), formed fol-
lowing activation at a 70-fold molar excess of CDPC,
Fig. 1. (A) Schematic representation of C-reactive protein-enzyme linked sorbent assay. Phosphocholine (black circle)–bovine serum albumin (hashed
circle)–horseradish peroxidase conjugate (PC–BSA–HRP) is added simultaneously with free CRP (pentagon) to microwells precoated with CRP.
Free CRP competes with immobilized CRP for binding to PC–BSA–HRP conjugate. Substrate (S; tetramethylbenzidine) is then added and product
(P) formation, measured spectrophotometrically at 450/630 nm, is inversely proportional to CRP concentration. (B) Turbidimetric-CRP assay
system. Immobilized PC (black circles) on latex particles (shaded circle) bind free CRP (pentagon) in solution (indicated by dashed lines) to form an
insoluble complex. The extent of complex formation, measured spectrophotometrically at 550 nm, is proportional to CRP concentration.
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did not exhibit any affinity for the BSA-coated micro-
wells, thereby confirming the specificity of the conjugate
for CRP (Fig. 2A). Further evidence in support of the
specific detection of CRP by conjugate CM-3A is shown
in Fig. 2B. Here, standards of either BSA or CRP were
prepared (0–50mg/L) and added to CRP-coated plates
(1 lg/ml) using the CM-3A conjugate for the detection
of CRP. The presence of BSA did not cause any sig-
nificant decrease in absorbance, thus confirming that the
CM-3A conjugate could determine the presence of
specimen CRP, while the presence of nonspecific protein
(BSA) did not inhibit the binding of the CM-3A con-
jugate to the immobilized CRP. All subsequent micro-
well assays were carried out using conjugate CM-3A.
CRP-ELSA
The dynamic range of the assay was 0–10mg/L
human CRP, which represents 0–500mg/L CRP in
specimens diluted 1/50 and subsequently tested in the
CRP-ELSA. Fig. 3 illustrates a typical standard curve
for the CRP-ELSA from which either human serum or
plasma CRP levels can be determined.
ELSA sensitivity of detection was 1.06mg/L CRP, as
calculated from the mean+ 2 standard deviations when
individual human plasma specimens, deficient in CRP,
were assayed (n ¼ 20), and is within normal CRP levels
in human plasma (0–6mg/L). CRP-ELSA reproduc-
ibility was 5.5% CV at 6.25mg/L (n ¼ 12), 7.6% CV at
50mg/L (n ¼ 12), and 14.0% CV at 500mg/L (n ¼ 12).
Following determination of CRP levels in human serum
specimens (n ¼ 28) assayed at dilutions of 1/50 and
1/300, results were plotted against the CRP concentra-
tions (range: 14.3–279mg/L) determined for identical
specimens by immunoturbidimetric (IT) assay (Dade
Behring, Newark, DE). The correlation coefficients
calculated by comparing both data sets were 0.93 for
specimens diluted at 1/50 and 0.94 for samples diluted at
1/300 in 50mM MES, 10mM calcium chloride, 25mM
sodium chloride, 0.1% (v/v) Tween 20, pH 6.0 (Fig. 4).
These human plasma specimens were also assayed in
identical buffers containing either 50mM Tris–HCl, pH
7.4, or 50mM sodium phosphate, pH 5.0, instead of
50mM MES pH 6.0. Although the alteration in diluent
pH had minimal effect on standard CRP detection,
specimen correlation coefficients against IT CRP data
were 0.79 and 0.85 in 50mM Tris–HCl, pH 7.4, and
50mM sodium phosphate, pH 5.0, respectively, indi-
cating that optimal specimen CRP detection occurs at
pH 6.0.
Increasing the reaction temperature to 37 C from
20 C did not cause a significant improvement in assay
sensitivity (data not shown). Furthermore, while 15min
incubation time did not facilitate optimal binding of
 
   
A
B
Fig. 2. (A) Plot of absorbance 450/630nm versus log [CRP] (mg/L) to
evaluate the functionality and specificity of PC–BSA–HRP conjugate
(CM-3A) for CRP. Microwells were coated with either 1 lg CRP (j),
100 ng CRP (r), or 100 ng BSA (N). CM-3A binding is evident for
CRP-coated microwells only and no conjugate binding to BSA-coated
microwells is observed. (B) Plot of absorbance 450/630nm versus log
[CRP] (r) or log [BSA] (mg/L) (j) at a microwell coating level of
100 ng CRP. Binding of conjugate CM-3A to CRP is not inhibited in
the presence of a nonspecific protein (BSA).
  
Fig. 3. Plot of absorbance 450/630 nm versus log [CRP] (mg/L) to il-
lustrate the CRP-ELSA standard curve (sigmoidal type) for human
CRP standards prepared in optimized assay diluent; 50mM Mes,
25mM sodium chloride, 10mM calcium chloride, 0.1% (v/v) Tween 20,
pH 6.0. Standards were assayed in duplicate and data points are given
as mean standard error. PC–BSA–HRP conjugate was also prepared
in this diluent and immediately added to CRP-coated microwells after
standard or specimen CRP addition. The assay was allowed to proceed
for 30min prior to a wash step and tetramethylbenzidine substrate
addition.
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CRP either to the PC–BSA–HRP conjugate or to the
CRP-coated microwells, an incubation time of 30min
was sufficient as there was no significant increase in
CRP binding between 30 and 60min incubation (data
not shown). Calcium ion presence was found to be
essential for PC/CRP binding and it was found that
10mM calcium chloride facilitated optimal interaction.
Under these CRP-ELSA conditions, the PC/CRP in-
teraction was decreased by approximately 20 to 35%,
at CRP concentrations less than 1mg/L, if the assay
diluent was modified to contain 150 or 300mM sodium
chloride, thus indicating that positive ions may inter-
fere with the calcium-mediated interaction between
CRP and PC.
Detection of CRP in canine sera confirms that the
CRP-ELSA is compatible with specimens of nonhuman
origin. Following CRP-ELSA analysis, using purified
human CRP as standard, alterations in canine serum
CRP levels were detectable postsurgery whereby both
elevation and diminution in canine CRP levels were
measurable. Specifically, a 10-fold increase in serum
CRP was detectable within 24 h of cruciate ligament
surgery while reduction in CRP level to 33.6mg/L is also
clearly measurable (Fig. 5A). Confirmation that CRP of
nonhuman (canine) origin is detectable is seen also in
Fig. 5B where a correlation coefficient of 0.89 is ob-
served following comparison of specimen CRP concen-
trations from 10 to 200mg/L (n ¼ 14) determined by
CRP-ELSA (specimen dilution of 1/10) and an IgG
[anti-canine CRP]–HRP enzyme immunoassay (Canine
CRP ELISA (Tridelta, Wicklow, Ireland); Product
code: TP803). Significantly, a near-identical correlation
coefficient of 0.88 is observed at specimen dilution of
1/50, confirming linearity of dilution for canine CRP
detection.
Turbidimetric detection of C-reactive protein
Evaluation of the PC–BSA coupling concentration
between 0.4 and 1.6mg/ml showed that 1mg PC–BSA
per 10mg EDAC-activated microspheres gave optimal
assay performance (data not shown). A typical t-CRP
calibration curve is shown in Fig. 6. The t-CRP assay
exhibits an assay range of 0.5–10mg/L, which equates to
a specimen CRP concentration range of 25–500mg/L,
assuming a 1/50 specimen dilution. t-CRP assay repro-
ducibility is 6.3% CV at 250mg/L (n ¼ 24), 8.4% CV at
100mg/L (n ¼ 24), and 15.6% at 50mg/L (n ¼ 24). A
significant correlation (Spearman correlation coeffi-
cient ¼ 0.78; p < 0:0001) was observed following the
evaluation of CRP levels (range: 25–361.9mg/L) in
human plasma specimens (n ¼ 28) by the t-CRP assay
and a commercial IT assay (Tina-quant CRP, Roche
A
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Fig. 5. (A) Determination of [CRP] (mg/L) in canine sera. These data
illustrate the change in CRP levels in canine sera obtained pre- and
postcruciate ligament surgery, from a single animal, as measured by
CRP-ELSA (black bars) and by a commercially available CRP-ELISA
system (white bars). All specimens were assayed in duplicate using
human CRP as standard material and data are given as mean+ stan-
dard error. (B) Linear regression analysis for canine CRP analyzed by
a commercially available CRP-ELISA and by CRP-ELSA. Specimens
were diluted at 1/10 prior to CRP-ELSA analysis and the correlation
coefficient was calculated to be 0.89.
 
Fig. 4. Linear regression analysis of human [CRP] (mg/L) determined
by conventional immunoturbidimetric assay (IT assay) and CRP-
ELSA methodology. Specimens were diluted at 1/50 and assayed as
described under Materials and methods, and the correlation coefficient
was calculated to be 0.93.
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Diagnostics, Mannheim, Germany). When known
amounts of purified human CRP (100, 200, 400 lg) were
added to CRP-deficient human plasma from a single
individual, a mean recovery of 99.7% was observed
(range: 90.7–112%), whereby 96.5, 181.5, and 449mg/L
CRP, respectively, was measurable. Furthermore, fol-
lowing evaluation of NIBSC human CRP (1st Interna-
tional Standard, 50mg/L), a mean ( standard
deviation) recovery of 52 2:19mg/L (104%; n ¼ 6) was
observed, indicating both t-CRP assay compatibility
with serum CRP and calibration accuracy.
Discussion
Here we describe two nonimmunological test systems
for the quantitative detection of C-reactive protein.
While both systems are dependent upon the calcium-
mediated interaction between PC and CRP, interaction
detection is by enzyme- or microsphere-labeled PC fol-
lowed by spectrophotometric or turbidimetric assess-
ment of PC/CRP binding, respectively.
Cytidine 50-diphosphocholine was initially activated
by periodate oxidation and conjugated to bovine serum
albumin by Schiff base formation [10] to produce
phosphocholinated-bovine serum albumin for sub-
sequent enzyme (HRP) or microsphere (carboxy-modi-
fied) attachment. Interestingly, BSA activated in this
manner could not be detected by SDS–PAGE, Western
blot analysis using IgG [anti-BSA], or silver staining
either because of reduced affinity for Coomassie brilliant
blue R dye or because of epitope disruption. None-
theless, following introduction of maleimide groups
(0.7–3.7 per PC–BSA molecule), modified PC–BSA was
capable of conjugation to SATA-modified HRP by
thioether bond formation to form PC–BSA–HRP
conjugates. Although these conjugates were capable of
detecting bound CRP following attachment to immo-
bilized PC–BSA (data not shown), the low sensitivity of
detection (100mg/L) was insufficient to facilitate robust
assay development. For this reason, the development of
a competitive CRP-enzyme-linked sorbent assay was
undertaken whereby immobilized and free specimen/
standard CRP competed for solution-phase PC–BSA–
HRP conjugate.
CRP-ELSA sensitivity of detection (1.06mg/L)
compares favorably with standard automated methods
for CRP quantification which generally exhibit detection
limits of 3–8mg/L [5]. It should be noted that the ob-
served correlation coefficient (r ¼ 0:94) between human
CRP levels simultaneously measured by CRP-ELSA
and immunoturbidimetry is superior to those previously
achieved (r ¼ 0:88) for the comparative study of canine
CRP detection by two immunometric methods, namely
ELISA and canine CRP-specific immunoturbidimetry
[14]. Furthermore, in the present study, the determina-
tion of canine CRP levels by CRP-ELSA correlates
closely (r ¼ 0:89) with those obtained by canine CRP-
specific ELISA. The CRP-ELSA dynamic range of
0–500mg/L, along with the observed multispecies CRP
detection capability, thus represents an improvement
over these conventional CRP assay formats.
To our knowledge, the turbidimetric-CRP assay de-
scribed here is the first single-step, nonimmunological
CRP test system. Specimen CRP and microsphere–PC
interaction is complete within 5min and no further
change in absorbance is observed even when the reac-
tion is allowed to proceed for up to 10min. The t-CRP
assay exhibits a broad dynamic range of 25–500mg/L
CRP and assay performance parameters—with regard to
recovery and linearity of dilution—comparable with all
immunoturbidimetric assay systems, and it requires no
specimen pretreatment. Although the t-CRP limit of
detection (25mg/L) is above the upper limit of normal
for human plasma CRP (0–6mg/L), it is comparable
with the detection limit of rapid immunological methods
for CRP detection. For instance, a detection limit of
12mg/L CRP has been described for a card-based
sandwich immunoassay utilizing gold-conjugated IgG
[anti-CRP] [15]. Assessment of PC–BSA–microsphere
stability indicates reagent stability for at least 1 month
following storage at 4 and 37 C and it is likely that the
4 C stability will extend based on the 37 C stability
data. The t-CRP assay can also be carried out using
laboratory-based spectrophotometers (data not shown).
To date, no plasma components which interfere with
CRP-ELSA or t-CRP performance have been detected;
however, further studies to confirm this observation will
be required.
In summary, two nonimmunological assay sys-
tems for the detection of CRP based solely upon the
 
 
Fig. 6. Plot of D absorbance 550 nm versus [CRP] (mg/L) following
turbidimetric analysis of purified human CRP. Standards were assayed
in duplicate and data points are given as mean standard error. The
assay was performed by adding 10 ll standards or specimens to 490ll
PC-labeled microspheres (0.03% (w/v)) in reaction cuvettes and al-
lowed to proceed at 37 C for 5min after which time the D absorbance
at 550 nm was computed. The ‘‘in tube’’ assay range is 0.5–10mg/L,
which equates to a specimen CRP concentration range of 25–500mg/L
(1/50 specimen dilution).
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calcium-dependent interaction between CRP and
phosphocholine (International Patent Application No.
PCT/IE 01/124) have been developed. The microwell-
based assay (CRP-ELSA) exhibits a detection limit of
1.06mg/L, can be completed in 60min and facilitates
multispecies CRP detection. The turbidimetric (t-CRP)
assay utilizes PC–BSA-coated microspheres, the total
assay time is 5min per specimen, and the assay is au-
tomatable and facilitates human CRP detection be-
tween 25 and 500mg/L.
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